- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dennis Scanlon, PhD, Describes How Consumers Can Make Informed Healthcare Decisions
Dennis Scanlon, PhD, professor of health policy and administration at Penn State University, says that it is important to consider what details patients need in order to make informed decisions. For payers, this might include informing consumers about enrollment decisions.
Dennis Scanlon, PhD, professor of health policy and administration at Penn State University, says that it is important to consider what details patients need in order to make informed decisions. For payers, this might include informing consumers about enrollment decisions. The health plan decisions that patients make during an enrollment period can have implications down the road.
“We need to get people to think about not only what the price is to enroll today, but what the implications may be in the future should the need arise for care,” says Dr Scanlon. He notes that consumers’ other lifestyle concerns, such as their retirement savings, may also shape their decision making. “[If] I’m healthy today I may want to go with a lower price option, but in doing so, I might be making decisions that ultimately that could impact me or adversely impact my decision down the road should I need significant care.”
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
